You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Sanofi’s oral BTK inhibitor rilzabrutinib fails Phase III trial

Sanofi has announced that its investigational oral Bruton’s tyrosine kinase (BTK) inhibitor rilzabrutinib failed to meet the primary and secondary endpoints in a Phase III trial.